U.S. markets closed

Relay Therapeutics, Inc. (RLAY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
33.08+1.02 (+3.18%)
At close: 4:00PM EDT
33.08 0.00 (0.00%)
After hours: 04:01PM EDT

Relay Therapeutics, Inc.

399 Binney Street
2nd Floor
Cambridge, MA 02139
United States
617 370 8837
http://www.relaytx.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees163

Key Executives

NameTitlePayExercisedYear Born
Mr. Alexis A. BorisyCo-Founder & Independent Chairman55.62kN/A1972
Dr. Sanjiv K. Patel MBBS, M.A., M.D., M.B.A.CEO, Pres & Director987.19kN/A1974
Dr. Mark MurckoCo-Founder & Director181kN/A1960
Mr. Brian R. Adams J.D.Gen. Counsel & Sec.568.05kN/A1974
Dr. Donald A. BergstromExec. VP and Head of R&D669.82kN/A1972
Mr. Thomas CatinazzoSr. VP of Fin.N/AN/A1977
Mr. Peter RahmerSr. VP of Corp. Affairs & Investor RelationsN/AN/AN/A
Dr. Deborah Palestrant Ph.D.VP of Corp. Devel. & StrategyN/AN/AN/A
Mr. Andy PorterExec. VP & Chief People OfficerN/AN/AN/A
Mr. Jim Watters Ph.D.Sr. VP of BiologyN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The company's lead product candidates include RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors; RLY-4008, an oral small molecule selective inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced solid tumors having oncogenic FGFR2 alterations; and RLY-PI3K1047, a lead compound that targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Relay Therapeutics, Inc.’s ISS Governance QualityScore as of July 1, 2021 is 8. The pillar scores are Audit: 7; Board: 7; Shareholder Rights: 7; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.